EBITDA: Income before interest, taxes, depreciation and amortization.
Seres Therapeutics, Inc. (MCRB) had EBITDA of $-18.42M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.44M |
|
$-15.34M |
|
-- |
|
$0.44M |
|
$19.82M |
|
$-19.38M |
|
$4.04M |
|
$-15.34M |
|
$-15.34M |
|
$-15.34M |
|
$-15.34M |
|
$-15.34M |
|
$-15.34M |
|
$-19.38M |
|
|
EBITDA |
$-18.42M |
8.86M |
|
8.87M |
|
$-1.79 |
|
$-1.78 |
|
| Balance Sheet Financials | |
$49.38M |
|
$7.63M |
|
$88.82M |
|
$138.19M |
|
$19.32M |
|
-- |
|
$74.65M |
|
$93.97M |
|
$44.22M |
|
$44.22M |
|
$44.22M |
|
9.56M |
|
| Cash Flow Statement Financials | |
$1.12M |
|
$-0.04M |
|
$13.90M |
|
$39.46M |
|
$54.43M |
|
$14.97M |
|
$10.84M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.56 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-4423.98% |
|
-4423.97% |
|
-- |
|
-3501.14% |
|
-3501.14% |
|
$1.07M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.85 |
|
106.23 |
|
-34.68% |
|
-34.68% |
|
-11.10% |
|
-34.68% |
|
$4.63 |
|
$0.12 |
|
$0.13 |
|